Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
L-Plastin Double Nickase Plasmid (h): sc-402131-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- L-Plastin Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- L-Plastin Double Nickase Plasmid (h) and L-Plastin Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting LCP1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: L-Plastin Antibody (B-9): sc-133218
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
L-Plastin Double Nickase Plasmid (h) | sc-402131-NIC | 20 µg | $410.00 | |||
L-Plastin Double Nickase Plasmid (h2) | sc-402131-NIC-2 | 20 µg | $410.00 |
LCP1 encodes L-plastin, an actin-bundling protein expressed predominantly in hematopoietic lineages that stabilizes filamentous actin networks and supports dynamic remodeling of the cytoskeleton. L-plastin contributes to integrin-dependent adhesion, cell motility, immune synapse formation, and phagocytic processes through coordination of actin turnover and signaling at the plasma membrane. Regulation by phosphorylation links L-plastin to pathways controlling leukocyte activation and trafficking, including chemokine-driven migration and inflammatory responses. Aberrant LCP1 expression or activity has been associated with altered immune cell behavior and has been studied in contexts such as tumor cell invasion, metastatic potential, and immune dysregulation.
L-Plastin Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the LCP1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within LCP1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt LCP1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of LCP1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.